Solvonis Therapeutics Names Professor David Nutt as Chief Scientific Officer

PUBLISHED: 03 Jun 2025 @ 18:31 | Comments (0) | More info about Fiona Craig

Solvonis Therapeutics Plc (LSE:SVNS) has announced the appointment of Professor David Nutt as its new Chief Scientific Officer—a strategic move aimed at strengthening its scientific direction and clinical development efforts. A globally recognized expert in neuroscience and psychiatric medicine, Professor Nutt will lead the advancement of Solvonis’ growing therapeutic pipeline, which includes key programs targeting Alcohol Use Disorder (AUD) and Post-Traumatic Stress Disorder (PTSD).

His appointment is expected to bring invaluable expertise to the company’s R&D initiatives and further solidify Solvonis’ focus on addressing pressing mental health challenges through innovative treatment approaches. Professor Nutt’s leadership is anticipated to enhance both the scientific credibility and the operational execution of Solvonis’ mission, potentially elevating its standing within the biopharmaceutical industry.

About Solvonis Therapeutics Plc

Solvonis Therapeutics is a London-based clinical-stage biopharma company dedicated to developing breakthrough treatments for addiction and mental health disorders. The company’s pipeline comprises both novel and repurposed compounds targeting high-need neuropsychiatric conditions such as AUD and PTSD. Listed on the London Stock Exchange, Solvonis aims to deliver impactful therapies for conditions that continue to lack effective, accessible solutions.

CLICK HERE TO REGISTER FOR FREE ON ADVFN, the world's leading stocks and shares information website, provides the private investor with all the latest high-tech trading tools and includes live price data streaming, stock quotes and the option to access 'Level 2' data on all of the world's key exchanges (LSE, NYSE, NASDAQ, Euronext etc).

This area of the ADVFN.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ADVFN Ltd. ADVFN Ltd does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ADVFN.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ADVFN.COM and is not intended to be relied upon by users in making (or refraining from making) any investment decisions. Authors may or may not have positions in stocks that they are discussing but it should be considered very likely that their opinions are aligned with their trading and that they hold positions in companies, forex, commodities and other instruments they discuss.